SEVERE ADVERSE EVENTS — INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not administered intrathecally. Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media.
Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Numerous factors, including length of procedure, catheter and syringe material, underlying disease state, and concomitant medications may contribute to the development of thromboembolic events. For these reasons, meticulous angiographic techniques are recommended including close attention to guidewire and catheter manipulation, use of manifold systems and/or three-way stopcocks, frequent catheter flushing with heparinized saline solutions and minimizing the length of the procedure. The use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of in vitro clotting.
Serious or fatal reactions have been associated with the administration of iodine-containing radiopaque media. It is of utmost importance to be completely prepared to treat any contrast medium reaction.
As with any contrast medium, serious neurologic sequelae, including permanent paralysis, can occur following cerebral arteriography, selective spinal arteriography and arteriography of vessels supplying the spinal cord. A cause-effect relationship to the contrast medium has not been established since the patients' pre-existing condition and procedural technique are causative factors in themselves. The arterial injection of a contrast medium should never be made following the administration of vasopressors since they strongly potentiate neurologic effects.
Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.
Intravascularly administered iodine-containing radiopaque media are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria. Myeloma occurs most commonly in persons over age 40. Although neither the contrast agent nor dehydration has been proved separately to be the cause of anuria in myelomatous patients, it has been speculated that the combination of both may be causative. The risk in myelomatous patients is not a contraindication to the procedure; however, special precautions, including maintenance of normal hydration and close monitoring, are required. Partial dehydration in the preparation of these patients prior to injection is not recommended since this may predispose the patient to precipitation of the myeloma protein.
Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risks, the procedures may be performed; however, the amount of radiopaque medium injected should be kept to an absolute minimum. The blood pressure should be assessed throughout the procedure, and measures for treatment of a hypertensive crisis should be available.
Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when administered intravascularly.
Reports of thyroid storm following the intravascular use of iodinated radiopaque agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule, suggest that this additional risk be evaluated in such patients before use of any contrast medium.
OPTIRAY (ioversol injection) formulations are sterile, nonpyrogenic, aqueous solutions intended for intravascular administration as diagnostic radiopaque media. Each bottle is to be used as a Pharmacy Bulk Package for dispensing multiple single dose preparations utilizing a suitable transfer device.
OPTIRAY 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. OPTIRAY 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. OPTIRAY 350 is indicated in children for angiocardiography.
OPTIRAY 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. OPTIRAY 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
OPTIRAY 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.
OPTIRAY 300 is indicated for cerebral angiography and peripheral arteriography. OPTIRAY 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.
OPTIRAY 240 is indicated for cerebral angiography and venography. OPTIRAY 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Media Articles Related to Optiray (Ioversol Intravascular)
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2016.05.31]
The U.S. Food and Drug Administration has approved Axumin, a radioactive diagnostic agent for injection.
Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.
Artificial enzymes used in wide range of household products are "potent allergens"
Source: Allergy News From Medical News Today [2016.09.22]
But no commercially available diagnostic tests to monitor this potential new health risk.
Molecular Testing of Cancers: 'Let's Try to Get It Right'
Source: Medscape Internal Medicine Headlines [2016.09.21]
Use of molecular diagnostics in cancer can be tricky, but Dr Lundberg says the pathologist can ask important questions to help guide the process.
Medscape Internal Medicine
Prenatal Ultrasound Tied to Autism Severity in At-Risk Kids
Source: Medscape Psychiatry & Mental Health Headlines [2016.09.21]
First-trimester diagnostic ultrasound has been linked to greater autism symptom severity, particularly in genetically vulnerable boys.
Medscape Medical News
Published Studies Related to Optiray (Ioversol Intravascular)
A very rare case of encephalopathy in a patient with end-stage renal disease: contrast agent, ioversol. 
Contrast agents are associated with a number of adverse effects, including central nervous system effects... Patients with end-stage renal disease may be at an increased risk of adverse effects of contrast agents.
Ioversol-induced acute generalized exanthematous pustulosis: a case report. [2009.06]
BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a relatively rare exfoliative dermatosis consisting of a generalized eruption of sterile, nonfollicular pustules arising on widespread erythematous and edematous skin that is usually caused by drugs...
Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. [2008.10]
BACKGROUND: Iso-osmolar contrast medium iodixanol has been reported to be less nephrotoxic than selected low-osmolar contrast media (LOCM) in chronic kidney disease (CKD) patients with diabetes mellitus. This study compared the nephrotoxicity of iodixanol and the LOCM ioversol in CKD patients undergoing coronary angiography... CONCLUSIONS: Overall, the nephrotoxicity associated with iodixanol was not significantly different from that observed with ioversol in CKD patients undergoing coronary angiography, although in diabetic patients, MPPC was significantly lower in the iodixanol group.
Fatal anaphylactoid reaction following ioversol administration. [2007.12]
We report a fatal intravenous ioversol administration in a 60-year old male patient. Although the introduction of new low-osmolar non-ionogenic contrast media with a more favourable efficacy-toxicity balance has diminished the side-effects significantly, everyone involved in radiodiagnostic procedures should be aware of the potential life-threatening effects.
Clinical Trials Related to Optiray (Ioversol Intravascular)
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography [Terminated]
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation [Completed]
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell
transplant, and radiographic evidence of mucosal inflammation will be correlated with the
subsequent development of acute graft versus host disease. The primary endpoint is the
feasibility and safety of contrast-enhanced abdominal CT in the early post-transplant
period, as defined by the risk of contrast-related nephropathy or allergic reaction.
Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography [Terminated]
The Effect of Contrast Agent on Endothelial Function in Healthy Men [Completed]
Contrast medium is essential for diagnosis of many diseases. However, recent studies showed
that contrast agents can induce renal injury and is associated with poor long-term clinical
outcome, especially in diabetes. To date, no data are available on the relationship between
contrast medium and endothelial function. Endothelial dysfunction is known to precede
atherosclerosis and is considered a risk marker for future development of cardiovascular
disease. Therefore, we hypothesized that contrast agents may induce endothelial dysfunction
in healthy men. In addition, we hypothesized that contrast induced endothelial dysfunction
via free radicals. Thus, we also test alpha-lipoic acid whether or not protect endothelial
dysfunction induced by contrast agents.
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver [Completed]
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and
keeping chemotherapy drugs near the tumor.
PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients
who have primary liver cancer or metastases to the liver that cannot be surgically removed.